IRVING, Texas, February 5, 2025 - McKesson Corporation (NYSE:MCK) today announced results for the third quarter ended December 31, 2024. Third Quarter Highlights: . Consolidated revenues of $95.3 billion increased 18%. Earnings per diluted share of $6.95 increased $2.53.

McKesson's broad set of specialty solutions, the financial results we consolidated with the McKesson's US Pharmaceutical segment. Upon closing, PRISM is anticipated to be approximately $0.20 to $0.30 accretive to McKesson's adjusted

5 days ago · McKesson (NYSE: MCK) Q3 2025 Earnings Call Feb 05, 2025, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants. Prepared Remarks: Operator. Please stand by. Welcome to ...

5 days ago · McKesson Corp reported strong third-quarter results with an 18% increase in revenue to $95.3 billion and a 16% growth in adjusted operating profit to $1.5 billion.

5 days ago · McKesson Q3 2025 Earnings Call Feb 05, 2025, 4: 30 p.m ... Prepared Remarks: Operator. Please stand by. Welcome to McKesson's third quarter fiscal 2025earnings conference call Please be advised ...

McKesson Corporation (NYSE:MCK) Q3 2025 Earnings Call Transcript February 5, 2025 Operator: Welcome to McKesson’s Third Quarter Fiscal 2025 Earnings Conference Call. Please be advised that today ...

4 days ago · McKesson Corporation, Q3 2025 Earnings Call, Feb 05, 2025 Feb. 05 McKesson Narrows FY 2025 EPS View to $32.55-$32.95, vs Prior Guidance of $32.40-$33 and FactSet Analyst Consensus of $32.68/Share

4 days ago · McKesson Corporation is a global leader in healthcare and dedicated to improving care in every setting — one product, one partner, one patient at a time. We partner with care providers, pharmacies, manufacturers and more to safely deliver the right medicines, medical products and healthcare services to the patients who need them, when they ...

McKesson Corporation. (NYSE:MCK) Q3 2025 Earnings Conference Call February 5, 2025 4:30 PM ETCompany ParticipantsRachel Rodriguez - VP of Investor...

5 days ago · On February 5, 2025, McKesson Corp (MCK, Financial) released its 8-K filing for the third quarter of fiscal 2025, ending December 31, 2024. McKesson, a leading pharmaceutical wholesaler in the U.S., reported consolidated revenues of $95.3 billion, marking an 18% increase from the previous year.